阿莫胃泌素 | 16870-37-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 阿莫胃泌素
• 英文名称: Amogastrin
• 英文别名: (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-(2-methylbutan-2-yloxycarbonylamino)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
• CAS: 16870-37-4
• 化学式: C₃₅H₄₆N₆O₈S
• 分子量: 710.8
• InChiKey: CAVZBWFUMSXZFB-LJWNLINESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  50
• 可旋转键数：
  20
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  247
• 氢给体数：
  7
• 氢受体数：
  9

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon
  申请人：——

  公开号：US20030125528A1

  公开（公告）日：2003-07-03

  An improved process is described for preparing Schiff base condensation adduct final products whose components comprise a protein having beneficial activity in animals, and an aromatic o-hydroxy aldehyde, which comprises bringing together the above-mentioned components in an aqueous environment at a pH of 7.0 or higher to form a reaction mixture, under conditions effective to drive said condensation reaction substantially to completion by removing from about 97.0% to about 99.9% by weight, preferably from about 98.0% to about 99.0% by weight of the water already present or produced during said condensation reaction, consistent with maintaining the integrity of the condensation reactants and adduct final product, and to assure a rate of conversion to said condensation adduct final product, i.e., with resulting yield of said condensation adduct final product of equal to or greater than about 98.5% by weight, preferably equal to or greater than about 99.5% by weight based on the weight of the reactants. Preferred aromatic o-hydroxy aldehydes comprise o-vanillin; salicylaldehyde; 2,3-dihydroxybenzaldehyde; 2,6-dihydroxybenz-aldehyde; 2-hydroxy-3-ethoxybenzaldehyde; or pyridoxal. A very wide range of proteins may be employed. The improved process provides yields over 90% and substantially quantitative conversion of the aldehyde and protein to the condensation adduct.

  本文描述了一种改进的方法，用于制备Schiff碱缩合加合物的最终产物，其组分包括在动物中具有有益活性的蛋白质和芳香族o-羟基醛。该方法包括在pH为7.0或更高的水环境中将上述组分结合在一起以形成反应混合物，通过有效的条件将缩合反应驱动到几乎完成，其中从已有的水分中或在缩合反应期间产生的水分中除去大约97.0%到99.9%的重量，最好是从98.0%到99.0%的重量，保持缩合反应物和加合物最终产物的完整性，并确保转化为所述缩合加合物最终产物的速率，即所得缩合加合物最终产物的产率等于或大于约98.5%的重量，最好等于或大于约99.5%的重量，基于反应物的重量。首选的芳香族o-羟基醛包括邻香草醛；水杨醛；2,3-二羟基苯甲醛；2,6-二羟基苯甲醛；2-羟基-3-乙氧基苯甲醛；或吡哆醛。可以使用非常广泛的蛋白质。改进的方法提供了超过90%的产率和几乎定量的醛和蛋白质转化为缩合加合物。
• Stable lipid emulsion
  申请人：Wakamoto Pharmaceutical Co., Ltd.

  公开号：EP0700678A1

  公开（公告）日：1996-03-13

  A lipid emulsion which comprises (A) an oil component, (B) an emulsifying agent containing yolk lecithin and/or soybean lecithin, and (C) water, wherein the lipid emulsion further comprises citric acid or a pharmaceutically acceptable salt thereof and at least one member selected from the group consisting of methionine, phenylalanine, serine, histidine and pharmaceutically acceptable salts thereof, provided that it does not simultaneously contain methionine and phenylalanine. The addition of citric acid and histidine, methionine, phenylalanine and/or serine to a lipid emulsion containing natural lecithin as an emulsifying agent permits the prevention of change of color and formation of oil drops associated with the conventional natural lecithin-containing lipid emulsion due to the synergistic effect of the foregoing additives. The drug-containing lipid emulsion is also excellent in storage stability and thus the foregoing lipid emulsion can be applied to drugs such as injections, eye drops, nasal drops, lotions or liniments, inhalants and drugs for oral administration or cosmetics such as humectants.

  一种脂质乳剂，它包括(A)油成分，(B)含有卵黄卵磷脂和/或大豆卵磷脂的乳化剂，以及(C)水，其中脂质乳剂还包括柠檬酸或其药学上可接受的盐，以及至少一种选自蛋氨酸、苯丙氨酸、丝氨酸、组氨酸及其药学上可接受的盐组成的组的成员，但它不能同时含有蛋氨酸和苯丙氨酸。在含有天然卵磷脂作为乳化剂的脂质乳液中添加柠檬酸和组氨酸、蛋氨酸、苯丙氨酸和/或丝氨酸，可防止传统的含天然卵磷脂脂质乳液因上述添加剂的协同作用而变色和形成油滴。这种含药物的脂质乳液还具有出色的储存稳定性，因此上述脂质乳液可用于注射剂、滴眼剂、滴鼻剂、洗剂或药剂、吸入剂和口服药物等药物或保湿剂等化妆品。
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS
  申请人：deJuan Eugene

  公开号：US20110159073A1

  公开（公告）日：2011-06-30

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.